TriCipher launches MySignatureBook for secure, fast and affordable electronic document signing
LONDON -- TriCipher today released the first digital document signing technology that gathers and stores multiple signatures on a single, centrally managed file. Unlike any other solution, TriCipher MySignatureBook(tm) (MSB) saves multiple signatures from a centrally managed, Web-based workflow to a single, unaltered document, relieving companies from manually tracking dozens of files each with a lone signature.
MSB is the only solution that ensures end-to-end security for highly regulated and sensitive documents, and eliminates time-consuming and costly paper-based signature processes, including shipping and storage.
Pfizer initially developed MySignatureBook and has been using it since the summer of 2006, in conjunction with its authentication credentials certified by the SAFE(tm) BioPharma Association, which provides the pharmaceutical industry's legal foundation for digital signatures. TriCipher has expanded the product's support for multiple credential types, making it easy for pharmaceutical, healthcare and financial services employees and customers to leverage digital signatures for high-risk and regulated activities.
For enterprises without a credential infrastructure, MSB supports the TriCipher Armored Credential System (TACS). This platform gives organisations user-friendly, low-cost, highly secure credentials, while maintaining the familiar username and password login experience and quickly enabling digital signing for all users.
About the Author(s)
You May Also Like
The fuel in the new AI race: Data
April 23, 2024Securing Code in the Age of AI
April 24, 2024Beyond Spam Filters and Firewalls: Preventing Business Email Compromises in the Modern Enterprise
April 30, 2024Key Findings from the State of AppSec Report 2024
May 7, 2024Is AI Identifying Threats to Your Network?
May 14, 2024
Black Hat USA - August 3-8 - Learn More
August 3, 2024Cybersecurity's Hottest New Technologies: What You Need To Know
March 21, 2024